Clinical Efficacy and Tolerability of Praziquantel for Intestinal and Urinary Schistosomiasis—A Meta-analysis of Comparative and Non-comparative Clinical Trials

PLoS Neglected Tropical Diseases

Volumn 8, Issue 11, 2014, Pages

  Zwang, Julien ^a   Olliaro, Piero L ^b,c  

^a Independent Researcher   (Thailand)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

OXAMNIQUINE; PRAZIQUANTEL;

ABDOMINAL PAIN; ARTHRALGIA; ARTICLE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEMATURIA; HUMAN; INCIDENCE; META ANALYSIS; MYALGIA; NAUSEA; RASH; SCHISTOSOMIASIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VERTIGO; VOMITING; WEAKNESS;

EID: 84920443817     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003286     Document Type: Article

References (85)

1. Steinmann P, Keiser J, Bos R, Tanner M, Utzinger J, (2006) Schistosomiasis and water resources development: systematic review, meta-analysis, and estimates of people at risk. Lancet Infect Dis 6: 411–425.
2. World Health Organization (2006) Preventive chemotherapy in human helminthiasis: coordinated use of anthelminthic drugs in control interventions: a manual for health professionals and programme managers. Available: whqlibdoc.who.int/publications/2006/9241547103_eng.pdf. Accessed 2/1/2014.
3. World Health Organization (2010) Report of a meeting to review the results of studies on the treatment of schistosomiasis in pre-school-age children. Available: http://whqlibdoc.who.int/publications/2011/9789241501880_eng.pdf. Accessed 2/1/2014.
4. World Health Organization (2013) Assessing The Efficacy Of Anthelminthic Drugs Against Schistosomiasis And Soil-Transmitted Helminthiases. Available: http://apps.who.int/iris/bitstream/10665/79019/1/9789241564557_eng.pdf. Accessed 2/1/2014.
5. World Health Organization (2001) Resolution 54.19 of the World Health Assembly, WHA 54.19. Available: www.who.int/neglected_diseases/mediacentre/WHA_54.19_Eng.pdf. Accessed 2/1/2014.
6. Kramer CV, Zhang F, Sinclair D, Olliaro PL, (2014) Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 6: CD000053.
7. Danso-Appiah A, Olliaro P, Utzinger J, (2013) Drugs for treating Schistosoma mansoni infection. Cochrane Database Syst Rev CD000528
8. Schistosomiasis Treatment for Preschool Children: TI Pharma (2013) Available: http://www.tipharma.com/pharmaceutical-research-projects/infectious-diseases/schistosomiasis.html. Accessed 2/1/2014.
9. Knopp S, Mohammed KA, Speich B, Hattendorf J, Khamis IS, et al. (2010) Albendazole and mebendazole administered alone or in combination with ivermectin against Trichuris trichiura: a randomized controlled trial. Clin Infect Dis 51(12): 1420–1428.
10. DerSimonian R, Laird N, (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188.
11. Juni B, Altman DG, Egger M, (2001) Systematic reviews of healthcare: assessing the quality of controlled clinical trials. BMJ 323: 42–6.
12. Pocock SJ, Travison TG, Wruck LM, (2008) How to interpret figures in reports of clinical trials. BMJ 336: 1166–1169.
13. Kramer CV, Zhang F, Sinclair D, Olliaro PL, (2014) Drugs for treating urinary schistosomiasis. Cochrane Database Syst Rev 8: CD000053.
14. Abu-Elyazeed RR, Mansour NS, Campbell JR, (1998) The prevalence and intensity of Schistosoma mansoni infection among residents in two Egyptian villages, at two and twelve months post-treatment with 40 and 60 mg praziquantel per kg body weight at these two villages respectively. J Egypt Soc Parasitol 28: 9–16.
15. Barakat R, Elmorshedy H, Fenwick A, (2005) Efficacy of myrrh in the treatment of human Schistosomiasis mansoni. Am J Trop Med Hyg 73: 365–7.
16. Belizario Jr VY, Amarillo MLE, Martinez RM, Mallari AO, Tai CMC, (2008) Efficacy and safety of 40 mg/kg and 60 mg/kg single doses of praziquantel in the treatment of schistosomiasis. Journal of Pediatric Infectious Diseases 3: 27–34.
17. Berhe N, Gundersen SG, Abebe F, Birrie H, Medhin G, et al. (1999) Praziquantel side effects and efficacy related to Schistosoma mansoni egg loads and morbidity in primary school children in north-east Ethiopia. Acta Trop 72: 53–63.
18. Borrmann S, Szlezak N, Faucher JF, Matsiegui PB, Neubauer R, et al. (2001) Artesunate and praziquantel for the treatment of Schistosoma haematobium infections: a double-blind, randomized, placebo-controlled study. J Infect Dis 184: 1363–1366.
19. Botros S, Sayed H, El-Dusoki H, Sabry H, Rabie I, et al. (2005) Efficacy of mirazid in comparison with praziquantel in Egyptian Schistosoma mansoni-infected school children and households. Am J Trop Med Hyg 72: 119–23.
20. Burchard GD, Kern P, Baltes R, Dietrich M, (1984) Comparative trial of oltipraz versus praziquantel in the treatment of urinary schistosomiasis in the Gabon. Tropenmed Parasitol 35: 91–94.
21. da Silva LC, Zeitune JM, Rosa-Eid LM, Lima DM, Antonelli RH, et al. (1986) Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Rev Inst Med Trop Sao Paulo 28: 174–180.
22. Davis A, Biles JE, Ulrich AM, (1979) Initial experiences with praziquantel in the treatment of human infections due to Schistosoma haematobium. Bull World Health Organ 57: 773–779.
23. De Clercq D, Vercruysse J, Kongs A, Verle P, Dompnier JP, et al. (2002) Efficacy of artesunate and praziquantel in Schistosoma haematobium infected schoolchildren. Acta Trop 82: 61–66.
24. De Clercq D, Vercruysse J, Verle P, Kongs A, Diop M, (2000) Short communication: What is the effect of combining artesunate and praziquantel in the treatment of Schistosoma mansoni infections? Trop Med Int Health 5: 744–746.
25. De Clercq D, Vercruysse J, Verle P, Niasse F, Kongs A DM, (2000) Efficacy of artesunate against Schistosoma mansoni infections in Richard Toll, Senegal. Trans R Soc Trop Med Hyg 94: 90–91.
26. Degu G, Mengistu G, Jones J, (2002) Praziquantel efficacy against schistosomiasis mansoni in schoolchildren in north-west Ethiopia. Trans R Soc Trop Med Hyg 96: 444–445.
27. El Tayeb M, Daffalla AA, Kardaman MW, See R, Fenwick A, (1988) Praziquantel and oltipraz: the treatment of schoolchildren infected with Schistosoma mansoni and/or Schistosoma haematobium in Gezira, Sudan. Ann Trop Med Parasitol 82: 53–57.
28. Friis H, Byskov J, (1989) The effect of praziquantel against Schistosoma mansoni-infections in Botswana. Trop Geogr Med 41: 49–51.
29. Ghandour AM, al-Robai AA, Doenhoff M, Banaja AA, (1995) Epidemiological studies on Schistosoma mansoni infection in the western region of Saudi Arabia using the potassium hydroxide stool digestion technique. J Trop Med Hyg 98: 57–63.
30. Gryseels B, Nkulikyinka L, Coosemans MH, (1987) Field trials of praziquantel and oxamniquine for the treatment of schistosomiasis mansoni in Burundi. Trans R Soc Trop Med Hyg 81: 641–644.
31. Guisse F, Polman K, Stelma FF, Mbaye A, Talla I, et al. (1997) Therapeutic evaluation of two different dose regimens of praziquantel in a recent Schistosoma mansoni focus in Northern Senegal. Am J Trop Med Hyg 56: 511–514.
32. Homeida MM, Eltom IA, Sulaiman SM, Ali HM, Bennett JL, (1989) Tolerance of two brands of praziquantel. Lancet 2: 391.
33. Hou XY, McManus DP, Gray DJ, Balen J, Luo XS, et al. (2008) A randomized, double-blind, placebo-controlled trial of safety and efficacy of combined praziquantel and artemether treatment for acute schistosomiasis japonica in China. Bull World Health Organ 86: 788–795.
34. Inyang-Etoh PC, Ejezie GC, Useh MF, Inyang-Etoh EC, (2009) Efficacy of a combination of praziquantel and artesunate in the treatment of urinary schistosomiasis in Nigeria. Trans R Soc Trop Med Hyg 103: 38–44.
35. Ismail MM, Attia MM, el-Badawy AA, Farghaly AM, Husein MH, et al. (1994) Treatment of schistosomiasis with praziquantel among school children. J Egypt Soc Parasitol 24: 487–494.
36. Kabatereine NB, Kemijumbi J, Ouma JH, Sturrock RF, Butterworth AE, et al. (2003) Efficacy and side effects of praziquantel treatment in a highly endemic Schistosoma mansoni focus at Lake Albert, Uganda. Trans R Soc Trop Med Hyg 97: 599–603.
37. Kardaman MW, Amin MA, Fenwick A, Cheesmond AK, Dixon HG, (1983) A field trial using praziquantel (BiltricideR) to treat Schistosoma mansoni and Schistosoma haematobium infection in Gezira, Sudan. Ann Trop Med Parasitol 77: 297–304.
38. Kardaman MW, Fenwick A, El Igail AB, El Tayeb M, Daffalla AA, et al. (1985) Treatment with praziquantel of schoolchildren with concurrent Schistosoma mansoni and S. haematobium infections in Gezira, Sudan. J Trop Med Hyg 88: 105–109.
39. Keiser J, N'Guessan NA, Adoubryn KD, Silué KD, Vounatsou P, et al. (2010) Efficacy and safety of mefloquine, artesunate, mefloquine-artesunate, and praziquantel against Schistosoma haematobium: randomized, exploratory open-label trial. Clin Infect Dis 50: 1205–1213.
40. Kern P, Burchard GD, Dietrich M, (1984) Comparative study of oltipraz versus praziquantel for treatment of schistosomiasis with intestinal manifestation in the Gabon (Schistosoma intercalatum and S. haematobium). Tropenmed Parasitol 35: 95–99.
41. King CH, Muchiri EM, Mungai P, Ouma JH, Kadzo H, et al. (2002) Randomized comparison of low-dose versus standard-dose praziquantel therapy in treatment of urinary tract morbidity due to Schistosoma haematobium infection. Am J Trop Med Hyg 66: 725–730.
42. Latham MC, Stephenson LS, Kurz KM, Kinoti SN, (1990) Metrifonate or praziquantel treatment improves physical fitness and appetite of Kenyan schoolboys with Schistosoma haematobium and hookworm infections. Am J Trop Med Hyg 43: 170–179.
43. Massoud AA, el Kholy AM, Anwar WA, (1984) Assessment of efficacy of praziquantel against Schistosoma mansoni infection. J Trop Med Hyg 87: 119–121.
44. McMahon JE, (1983) A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium. Ann Trop Med Parasitol 77: 139–142.
45. McMahon JE, Kolstrup N, (1979) Praziquantel: a new schistosomicide against Schistosoma haematobium. Br Med J 2: 1396–9.
46. McMahon JE, (1981) Praziquantel: a new schistosomicide against Schistosoma mansoni. Arzneimittelforschung 31: 592–594.
47. Metwally A, Bennett J, Botros S, Ebeid F, el attar Gel D, (1995) Impact of drug dosage and brand on bioavailability and efficacy of praziquantel. Pharmacol Res 31: 53–59.
48. Midzi N, Sangweme D, Zinyowera S, Mapingure MP, Brouwer KC, et al. (2008) Efficacy and side effects of praziquantel treatment against Schistosoma haematobium infection among primary school children in Zimbabwe. Trans R Soc Trop Med Hyg 102: 759–766.
49. Mohamed AA, Mahgoub HM, Magzoub M, Gasim GI, Eldein WN, et al. (2009) Artesunate plus sulfadoxine/pyrimethamine versus praziquantel in the treatment of Schistosoma mansoni in eastern Sudan. Trans R Soc Trop Med Hyg 103: 1062–1064.
50. Navaratnam AM, Sousa-Figueiredo JC, Stothard JR, Kabatereine NB, Fenwick A, et al. (2012) Efficacy of praziquantel syrup versus crushed praziquantel tablets in the treatment of intestinal schistosomiasis in Ugandan preschool children, with observation on compliance and safety. Trans R Soc Trop Med Hyg 106: 400–407.
51. N'Goran EK, Utzinger J, Gnaka HN, Yapi A, N'Guessan NA, et al. (2003) Randomized, double-blind, placebo-controlled trial of oral artemether for the prevention of patent Schistosoma haematobium infections. Am J Trop Med Hyg 68: 24–32.
52. Obonyo CO, Muok EM, Mwinzi PN, (2010) Efficacy of artesunate with sulfalene plus pyrimethamine versus praziquantel for treatment of Schistosoma mansoni in Kenyan children: an open-label randomised controlled trial. Lancet Infect Dis 10: 603–611.
53. Olds G, King C, Hewlett J, Olveda R, Wu G, et al. (1999) Double-blind placebo controlled study of the concurrent administration of albendazole and praziquantel in schoolchildren infected with schistosomiasis. J Infect Dis 179: 996–1003.
54. Olliaro PL, Vaillant MT, Belizario VJ, Lwambo NJ, Ouldabdallahi M, et al. (2011) A multicentre randomized controlled trial of the efficacy and safety of single-dose praziquantel at 40 mg/kg vs. 60 mg/kg for treating intestinal schistosomiasis in the Philippines, Mauritania, Tanzania and Brazil. PLoS Negl Trop Dis 5: e1165.
55. Oyediran AB, Kofie BA, Bammeke AO, Bamgboye EA, (1981) Clinical experience with praziquantel in the treatment of Nigerian patients infected with S. haematobium. Arzneimittelforschung 1: 581–584.
56. Raso G, N'Goran EK, Toty A, Luginbühl A, Adjoua CA, et al. (2004) Efficacy and side effects of praziquantel against Schistosoma mansoni in a community of western Côte d'Ivoire. Trans R Soc Trop Med Hyg 98: 18–27.
57. Rey JL, Sellin B, Gazere O, Ott D, Reges M, et al. (1983) Comparaison au Niger de l'efficacité sur Schistosoma haematobium du praziquantel (30 mg/kg et 40 mg/kg) en une prise et de l'oltipraz (35 mg/kg) en deux prises. Médecine et Maladies Infectieuses 13: 328–331.
58. Simonsen PE, Nega A, Furu P, (1990) Intestinal schistosomiasis among children in a labour village of Wonji Sugar Estate, Ethiopia. East Afr Med J 67: 532–538.
59. Sissoko MS, Dabo A, Traore H, Diallo M, Traore B, et al. (2009) Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 4: e6732.
60. Sousa-Figueiredo JC, Betson M, Atuhaire A, Arinaitwe M, Navaratnam AM, (2012) Performance and safety of praziquantel for treatment of intestinal schistosomiasis in infants and preschool children. PLoS Negl Trop Dis 6: e1864.
61. Stelma FF, Sall S, Daff B, Sow S, Niang M, et al. (1997) Oxamniquine cures Schistosoma mansoni infection in a focus in which cure rates with praziquantel are unusually low. J Infect Dis 176: 304–307.
62. Taddese K, Zein ZA, (1988) Comparison between the efficacy of oxamniquine and praziquantel in the treatment of Schistosoma mansoni infections on a sugar estate in Ethiopia. Ann Trop Med Parasitol 82: 175–180.
63. Taylor P, Murare HM, Manomano K, (1988) Efficacy of low doses of praziquantel for Schistosoma mansoni and S. haematobium. J Trop Med Hyg 91: 13–17.
64. Tchuente LA, Shaw DJ, Polla L, Cioli D, Vercruysse J, (2004) Efficacy of praziquantel against Schistosoma haematobium infection in children. Am J Trop Med Hyg 71: 778–782.
65. Teesdale CH, Chitsulo L, Pugh RN, (1984) Oxamniquine dosage in Malawi. East Afr Med J 61: 40–44.
66. Thiong'o FW, Mbugua GG, Ouma JH, Sturrock RK, (2002) Efficacy of oxamniquine and praziquantel in school children from two Schistosoma mansoni endemic areas. East Afr Med J 79: 29–33.
67. Utzinger J, N'Goran EK, N'Dri A, Lengeler C, Tanner M, (2000) Efficacy of praziquantel against Schistosoma mansoni with particular consideration for intensity of infection. Tropical Trop Med Int Health 5: 771–778.
68. Wilkins HA, Moore PJ, (1987) Comparative trials of regimes for the treatment of urinary schistosomiasis in The Gambia. J Trop Med Hyg 90: 83–92.
69. Al-Aska AK, Al-Mofleh IA, Al-Rashed RA, Hafez MA, Al-Nozha M, et al. (1990) Praziquantel, oxamniquine, and metrifonate in the treatment of schistomiasis in Riyad. Annals of Saudi medicine 10: 296–298.
70. Asfaw Z, Wolde-Michael T, Wondimagegnehu T, (1988) Assessment of side-effects of praziquantel in a trial treatment of Schistosoma haematobium infections in the Afar ethnic group of Ethiopia. Ethiop Med J 26: 85–89.
71. Chen MG, Hua XJ, Wang MJ, Xu RJ, Yu CB, et al. (1985) Dose finding double-blind clinical trial with praziquantel in schistosomiasis japonica patients. Southeast Asian J Trop Med Public Health 16: 228–233.
72. Da Silva LC, Zeitune JM, Rosa-Eid LM, Lima DM, Antonelli RH, et al. (1986) Treatment of patients with schistosomiasis mansoni: a double blind clinical trial comparing praziquantel with oxamniquine. Rev Inst Med Trop Sao Paulo 28: 174–180.
73. de Rezende GL, (1985) Survey on the clinical trial results achieved in Brazil comparing praziquantel and oxamniquine in the treatment of mansoni schistosomiasis. Rev Inst Med Trop Sao Paulo 27: 328–336.
74. Fernandes P, Oliveira C, (1986) Estudo comparative da eficacia do praziquantel, em dois esquemas posologicos, e da oxaminiquina no tratamento da esquistossomose mansonica F med(BR). 93: 389–393.
75. Jaoko WG, Muchemi G, Oguya FO, (1996) Praziquantel side effects during treatment of Schistosoma mansoni infected pupils in Kibwezi, Kenya East Afr Med J. 73: 499–501.
76. Ishizaki T, Kamo E, Boehme K, (1979) Double-blind studies of tolerance to praziquantel in Japanese patients with Schistosoma japonicum infections. 57: 787–791.
77. Katz N, Rocha RS, (1982) Double-blind clinical trial comparing praziquantel with oxamniquine in schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo 24: 310–314.
78. McMahon JE, (1983) A comparative trial of praziquantel, metrifonate and niridazole against Schistosoma haematobium. Ann Trop Med Parasitol 77: 139–142.
79. Omer AH, (1981) Praziquantel in the treatment of mixed S. haematobium and S. mansoni infections. Arzneimittelforschung 31: 605–608.
80. Queiroz LC, Drummond SC, Matos ML, Paiva MB, Batista TS, et al. (2010) Comparative randomised trial of high and conventional doses of praziquantel in the treatment of schistosomiasis mansoni. Mem Inst Oswaldo Cruz 105: 445–448.
81. Santos AT, Blas BL, Noseñas JS, Portillo GP, Ortega OM, et al. (1979) Preliminary clinical trials with praziquantel in Schistosoma japonicum infections in the Philippines. Bull World Health Organ 57: 793–799.
82. Sissoko MS, Dabo A, Traoré H, Diallo M, Traoré B, et al. (2009) Efficacy of artesunate + sulfamethoxypyrazine/pyrimethamine versus praziquantel in the treatment of Schistosoma haematobium in children. PLoS One 4: e6732.
83. Wu MH, Wei CC, Xu ZY, Yuan HC, Lian WN, et al. (1991) Comparison of the therapeutic efficacy and side effects of a single dose of levo-praziquantel with mixed isomer praziquantel in 278 cases of schistosomiasis japonica. Am J Trop Med Hyg 45: 345–349.
84. Olliaro P, Delgado-Romero P, Keiser J, (2014) The little we know about the pharmacokinetics and pharmacodynamics of praziquantel (racemate and R-enantiomer). J Antimicrob Chemother 69: 863–870.
85. Danso-Appiah A, Garner P, Olliaro PL, Utzinger J, (2009) Treatment of urinary schistosomiasis: methodological issues and research needs identified through a Cochrane systematic review. Parasitology 136: 1837–1849.